Major Depressive Disorder

Healio Psychiatry has compiled a list of its five most-viewed stories in June.

Apparent major depressive episodes after COVID-19 illness appeared distinct from those usually observed among adults, according to results of a survey study in a research letter published in JAMA Network Open.

Esmethadone, a once-daily pill for major depressive disorder, demonstrated rapid, robust and sustained antidepressant effects.

Frontline health care workers responding to the COVID-19 pandemic may benefit from a transdiagnostic, symptom-based approach regarding links between their acute psychopathology and burnout and functional difficulties.

Patients with major depressive disorder and inflammatory bowel disease had increased morbidity and discharge rates to non-home settings as well as increased heathcare burden, according to research presented at Digestive Disease Week.

Individuals with mental disorders were at increased risk for suicide, according to results of a systematic review and meta-regression analysis published in Journal of Psychiatric Research.

The number of Americans living with a mental illness is at an all-time high, exacerbated in 2020 by a global pandemic, political tensions across the country and economic uncertainty.

The Janssen Pharmaceutical Companies of Johnson & Johnson have announced European Commission authorization of expanded use of its esketamine nasal spray Spravato among adults with a moderate to severe episode of major depressive disorder.

Chronobiological alterations appeared directly linked to passive and active suicidal ideation and preparation, according to study results published in Journal of Clinical Psychiatry.

Researchers have developed a novel test to predict mood disorders based on levels of a protein found in the brain, according to study results published in Journal of Psychiatric Research.